3 active not recruiting, 3 not yet recruiting, 2 completed, 2 recruiting. 10 Phase 2, 4 Phase 3, 2 Not applicable, 1 Early Phase 1, 1 Phase 1.
Follow T Acute Lymphoblastic Leukemia: new trials by email Literature Review of T Acute Lymphoblastic Leukemia trials Research Report on T Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL CD7 CAR-T cell intravenous infusion - T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-03-15 | 2026-03-17 |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-09 | 2024-05-17 | |
| Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" Daratumumab Injection - T Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Tata Memorial Centre | 18 | 2023-08-28 | 2025-06-15 |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Biospecimen Collection, Calaspargase Pegol, Levocarnitine - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | Children's Oncology Group | 440 | 2023-08-24 | 2026-08-21 |
| Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL bone marrow and/or peripheral blood samples withdrawal - T Acute Lymphoblastic Leukemia, Early T Acute Lymphoblastic Leukemia | Not applicable | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 32 | 2021-05-19 | 2024-02-07 |
| RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL RD13-01 cell infusion - T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma | Not applicable | Unknown | Min Xiang | 24 | 2020-11-15 | 2020-11-09 |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting Azacitidine, Venetoclax - Acute Bilineal Leukemia, Acute Biphenotypic Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 100 | 2020-05-05 | 2026-10-05 |
| Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase, Cyclophosphamide, Doxorubicin Hydrochloride - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 2 | Withdrawn | University of Washington | 2018-07-01 | 2018-11-14 | |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 | Terminated | University of Southern California | 3 | 2018-05-09 | 2021-11-30 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 352 | 2017-08-08 | 2026-10-05 |
| Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2017-04-06 | 2025-03-03 |
| Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia Laboratory Biomarker Analysis, Pembrolizumab - B Acute Lymphoblastic Leukemia, Minimal Residual Disease | Phase 2 | Terminated | University of Washington | 12 | 2017-01-13 | 2020-08-20 |
| Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 160 | 2007-07-11 | 2026-10-08 |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Asparaginase, Cyclophosphamide, Cytarabine - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1895 | 2007-01-30 | 2026-06-23 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (17) · Burkitt Lymphoma (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia, Biphenotypic, Acute (4) · Leukemia, Myeloid, Acute (2) · Lymphoma (2) · Neoplasm, Residual (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (1)
Hematologic Diseases (17) · Hemic and Lymphatic Diseases (17) · Immune System Diseases (17) · Immunoproliferative Disorders (17) · Leukemia (17) · Leukemia, Lymphoid (17) · Lymphatic Diseases (17) · Lymphoproliferative Disorders (17) · Neoplasms (17) · Neoplasms by Histologic Type (17) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · DNA Virus Infections (7) · Epstein-Barr Virus Infections (7) · Herpesviridae Infections (7) · Infections (7)
Vincristine (9) · Asparaginase (8) · Cyclophosphamide (8) · Doxorubicin (8) · Cytarabine (7) · Calcium Dobesilate (6) · Dexamethasone (6) · Mercaptopurine (6) · Methotrexate (6) · auricularum (6) · dexamethasone 21-phosphate (6) · dexamethasone acetate (6) · merphos (6) · pegaspargase (6) · Daunorubicin (5)
Children's Oncology Group (3) · National Cancer Institute (NCI) (3) · University of Washington (3) · M.D. Anderson Cancer Center (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Min Xiang (1) · SWOG Cancer Research Network (1) · Tata Memorial Centre (1) · University of Southern California (1)
United States (10) · Canada (3) · Australia (2) · Italy (2) · New Zealand (2) · Switzerland (2) · Austria (1) · Belgium (1) · Chile (1) · China (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Hong Kong (1)
Ryan Cassaday (2) · Akil Merchant, MD (1) · Andrea Biondi (1) · Aref Al-Kali (1) · Betul Oran (1) · Etan Orgel (1) · Farhad Ravandi-Kashani (1) · Ibrahim Aldoss (1) · Keith J August (1) · Kristen M O'Dwyer (1) · Lewis B Silverman (1) · Ryan D. Cassaday, MD (1) · Stuart S Winter (1) · Sumeet Mirgh, MD, DM (1) · Xian Zhang (1)
PMID 16195338, PMID 19141862, PMID 21719599, PMID 22442346, PMID 25966987, PMID 25999452, PMID 26308596, PMID 27216216, PMID 27618682, PMID 27913532, PMID 28494052, PMID 29127588, PMID 29305553, PMID 29358182, PMID 29884853, PMID 30037340, PMID 30138085, PMID 30498492, PMID 31435023, PMID 31452197, PMID 32244252, PMID 32439800, PMID 32552472, PMID 32619115, PMID 32653327, PMID 32686081, PMID 32692850, PMID 32813610, PMID 32970151, PMID 33026700, PMID 33588922, PMID 33635331, PMID 34151693, PMID 34302711, PMID 34824885, PMID 35021604, PMID 36603187, PMID 37556734, PMID 37960985, PMID 40533067, PMID 41592282, PMID 42085640
U10CA180886 (3), P30CA015704 (2), U10CA180888 (2), 2017 (1), N01CM00099 (1), P30CA014089 (1), U10CA098543 (1), U24CA196173 (1), UG1CA189955 (1), UM1CA186686 (1)